Sophoricoside (SOP) improves lipopolysaccharides (LPS)-induced acute lung injury (ALI) in mice by activating the adenosine monophosphate-activated protein kinase (AMPK)/nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway. It also improves contact dermatitis by inhibiting the nuclear factor-kappa B (NF-κB) pathway in B cells in mice model.
Sophoricoside elicits anti-cancer, immunosuppressive, and anti-inflammatory activities.
[1] It inhibits proinflammatory cytokine production in human mast cells and has the potential to treat allergic inflammation diseases.
[1]